Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy.

Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy.

Definitive chemoradiotherapy (CRT) is a less invasive therapy for esophageal squamous cell carcinoma (ESCC). Five-year survival rate of locally advanced ESCC patients by definitive CRT were 37%. We previously reported that tumor-specific cytotoxic T-lymphocyte (CTL) activation signatures were prefer...

Full description

Bibliographic Details
Main Authors: Yosuke Tanaka, Kazuhiko Aoyagi, Keiko Minashi, Rie Komatsuzaki, Masayuki Komatsu, Fumiko Chiwaki, Masashi Tamaoki, Takao Nishimura, Naoki Takahashi, Ichiro Oda, Yuji Tachimori, Tokuzo Arao, Kazuto Nishio, Shigehisa Kitano, Kenta Narumi, Kazunori Aoki, Satoshi Fujii, Atsushi Ochiai, Teruhiko Yoshida, Manabu Muto, Yasuhide Yamada, Hiroki Sasaki
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0143804

Internet

https://doi.org/10.1371/journal.pone.0143804

Similar Items